Development

Articles

Strong immune response by patients receiving two doses of vaccine suggests a possible treatment strategy.

AstraZeneca Vaccine Shows Antibody and T-cell responses

SGS has announced the receipt of approval from Belgium’s Federal Agency for Medicines and Health Products (FAMHP) to begin a new clinical trial of a potential treatment for patients with COVID-19 related respiratory failure.

SGS Initiates Clinical Trial of Biophytis’ Treatment for COVID-19 Related Respiratory Failure

GlaxoSmithKline (GSK) and Medicago have announced a collaboration for the development and evaluation of a COVID-19 vaccine candidate. 

GSK, Medicago Collaborate on Covid-19 Vaccine Candidate

The European Directorate for the Quality of Medicines and Healthcare (EDQM) has published a new general chapter (2.6.32) in the European Pharmacopoeia (Ph. Eur.) supplement 10.3.

EDQM Publishes New General Chapter in European Pharmacopoeia Supplement 10.3

Full results from the Phase III ETHOS trial have demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations in patients with moderate to very severe COPD after treatment with triple-combination therapy Breztri Aerosphere.

Phase III Trial Results Demonstrate Benefit of AstraZeneca’s Breztri Aerosphere

Biotechnology company, ILC Therapeutics, has revealed  that it has entered into a research partnership with the University of St Andrews aimed at progressing a therapeutic drug that can treat COVID-19 to clinical trials.

ILC Therapeutics Enters Research Agreement with University of St Andrews

Biopharmaceutical company, Atriva Therapeutics, has announced, in a May 28, 2020 press release, that it will develop ATR-002, an oral small molecule, for treatment of patients with moderate-to-severe COVID-19 that require hospitalization in a Phase II study.

Atriva Therapeutics Announces Clinical Strategy to Treat COVID-19 Patients

Merck will acquire Themis Bioscience and collaborate with IAVI and Ridgeback Bio on COVID-19 vaccines and therapies.

Merck Announces Acquisition, Collaborations for Developing COVID-19 Vaccines and Therapies

A new strategic plan from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, details the institute’s plan for accelerating research to diagnose, prevent and treat COVID-19.

NIAID Plan Describes COVID-19 Research Priorities

US government and industry partners will coordinate to bring the most promising COVID-19 vaccine and treatment candidates to clinical trials.

Early Phase Development